Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

In the absence of cures for multi-system inflammatory disease, therapies aim to dampen long-term inflammation, control symptoms and prevent tissue damage. Glucocorticoids (GC) are a key ...

Background Single-cell RNA-sequencing (scRNA-seq) has been recently applied in systemic lupus erythematosus (SLE) to define distinct cellular composition and transcriptional signatures, greatly ...

Background/ Purpose Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when compared with prior ‘usual care.’ ...

O37 Male gender, educational level, disease activity, prednisone daily dose and previous medical adherence are predictive of medical adherence in systemic lupus erythematosus patients – Data from the ...

Objective Discrepancies in illness representations between patients and physicians result in treatment difficulties, decreased well-being of patients and misunderstandings and disrupted communication.

Conclusion The SLE-DAS cut-off for SDA provides an accurate definition of SDA in SLE, with good discriminative power and consistent associations with worse HR-QoL. This SLE-DAS definition enhances ...

Objective Fatigue has been reported as the most disturbing symptom in a majority of patients with SLE. Depression is common and often severe. Together these symptoms cause significant morbidity and ...

Background There is clear evidence that clinical and laboratory features of systemic lupus erythematosus (SLE) can be present for many years prior to an individual fulfilling the full disease ...

Background Systemic lupus erythematosus (SLE) is a complex disease caused by interplay of genetic predisposition and environmental triggers. Strong genetic component in lupus supported by familial ...

Objective To explore the efficacy of initial treatment of newly diagnosed childhood-onset lupus nephritis (cLN) with combination of belimumab and either cyclophosphamide, mycophenolate mofetil, ...

Background Mycophenolic acid (MPA) is recommended for the treatment of lupus nephritis (LN). However, the high pharmacokinetic (PK) variability of MPA contributes to its suboptimal efficacy and an ...